国际医药卫生导报 ›› 2023, Vol. 29 ›› Issue (24): 3542-3545.DOI: 10.3760/cma.j.issn.1007-1245.2023.24.004

• 医学新进展 • 上一篇    下一篇

白细胞相关免疫球蛋白样受体1在糖尿病中的研究现状

杨玲瑜  金勇君   

  1. 滨州医学院烟台附属医院内分泌科,烟台 264000

  • 收稿日期:2023-06-05 出版日期:2023-12-15 发布日期:2024-01-04
  • 通讯作者: 金勇君,Email:endojin@126.com

Leukocyte-associated immunoglobulin-like receptor 1 in diabetes

Yang Lingyu, Jin Yongjun   

  1. Department of Endocrinology, Yantai Hospital Affiliated to Binzhou Medical University, Yantai 264100, China

  • Received:2023-06-05 Online:2023-12-15 Published:2024-01-04
  • Contact: Jin Yongjun, Email: endojin@126.com

摘要:

白细胞相关免疫球蛋白样受体1(LAIR-1)是一种免疫抑制受体,介导了免疫抑制,可以通过调节炎症反应来影响多种代谢性及免疫性疾病的发生发展。糖尿病是导致胰岛素产生缺陷的最常见的疾病形式。现在公认的是炎症反应是对高血糖水平免疫反应的结果,这种低度的慢性炎症损害了胰腺的β细胞,并导致胰岛素分泌不足,从而导致高血糖。在这篇综述中,我们重点讲述了糖尿病发生机制、炎症引起胰岛素抵抗导致糖尿病以及LAIR-1免疫激活后开启下游抑制信号通路调节炎症反应。

关键词:

2型糖尿病, 白细胞相关免疫球蛋白样受体1, 炎症, 胰岛素抵抗, 综述

Abstract:

Leukocyte-associated immunoglobulin-like receptor-1 (LAIR-1) is an immune inhibitory receptor that mediates immune suppression. It can affect the occurrence and development of various metabolic and immune diseases by regulating inflammatory responses. Type 2 diabetes mellitus is the most common form of disease that leads to insulin production defects. It is now recognized that the inflammatory response is a result of immune response to high blood glucose levels. This low-grade chronic inflammation damages the beta cells of the pancreas and leads to insufficient insulin secretion, resulting in high blood glucose. This review elaborates on the mechanism of inflammation in type 2 diabetes mellitus and the impact of LAIR-1 on its development.

Key words:

Type 2 diabetes mellitus, Leukocyte-associated immunoglobulin-like receptor-1, Inflammation, Insulin resistance, Review